Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012:2012:863264.
doi: 10.1155/2012/863264. Epub 2012 Dec 24.

Tolerance induction strategies in vascularized composite allotransplantation: mixed chimerism and novel developments

Affiliations
Review

Tolerance induction strategies in vascularized composite allotransplantation: mixed chimerism and novel developments

David A Leonard et al. Clin Dev Immunol. 2012.

Abstract

Since the start of the clinical vascularized composite allotransplantation (VCA) era over a decade ago this field has witnessed significant developments in both basic and translational research. Transplant tolerance, defined as rejection-free acceptance of transplanted organs or tissues without long-term immunosuppression, holds the potential to revolutionize the field of VCA by removing the need for life-long immunosuppression. While tolerance of organ and vascularized composite transplants may be induced in small animal models by a variety of protocols, only mixed-chimerism-based protocols have successfully bridged the gap to preclinical study and to clinical trial in solid organ transplantation to date. In this paper we review the mixed-chimerism approach to tolerance induction, with specific reference to the field of VCA transplantation, and provide an overview of some novel cellular therapies as potential adjuvants to mixed chimerism in the development of tolerance induction protocols for clinical vascularized composite allotransplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms of tolerance in mixed chimerism.

Similar articles

Cited by

References

    1. Gibson T, Medawar PB. The fate of skin homografts in man. Journal of Anatomy. 1943;77:299–310. - PMC - PubMed
    1. Siemionow M, Klimczak A. Advances in the development of experimental composite tissue transplantation models. Transplant International. 2010;23(1):2–13. - PubMed
    1. Morelon E, Kanitakis J, Petruzzo P. Immunological issues in clinical composite tissue allotransplantation: where do we stand today? Transplantation. 2012;93(9):855–859. - PubMed
    1. Kouwenhoven EA, IJzermans JNM, de Bruin RWF. Etiology and pathophysiology of chronic transplant dysfunction. Transplant International. 2000;13(6):385–401. - PubMed
    1. Petruzzo P, Kanitakis J, Badet L, et al. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. American Journal of Transplantation. 2011;11(4):808–816. - PubMed

MeSH terms

LinkOut - more resources